Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: fenretinide Clear all
Not listed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Solid Tumors

NCT00009932
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cisplatin, fenretinide, paclitaxel
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 19, 2026, 3:37 PM EDT
Terminated Phase 1 Interventional

Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL

NCT01187810
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
Interventions
Fenretinide, Cytarabine, Methotrexate
Drug
Lead sponsor
South Plains Oncology Consortium
Network
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 19, 2026, 3:37 PM EDT
Completed Phase 2 Interventional

Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma

NCT00053326
View directory record Official record
Conditions
Recurrent Neuroblastoma
Interventions
fenretinide, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Oct 19, 2026, 3:37 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma

NCT02075177
View directory record Official record
Conditions
Recurrent Neuroblastoma, Neuroblastoma
Interventions
Fenretinide Lym-X-Sorb Oral Powder, Ketoconazole
Drug
Lead sponsor
South Plains Oncology Consortium
Network
Eligibility
Not listed
U.S. locations
3
States / cities
Oklahoma City, Oklahoma • Dallas, Texas • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 19, 2026, 3:37 PM EDT
Not listed Phase 2 Interventional

Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas

NCT02495415
View directory record Official record
Conditions
Peripheral T-cell Lymphoma
Interventions
Fenretinide
Drug
Lead sponsor
CerRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
11
States / cities
Gilbert, Arizona • Los Angeles, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 19, 2026, 3:37 PM EDT
Completed Phase 3 Interventional

Fenretinide in Treating Patients With Cervical Neoplasia

NCT00003075
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
Fenretinide, Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 19, 2026, 3:37 PM EDT
Terminated Phase 2 Interventional

Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme

NCT00075491
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
fenretinide, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 19, 2026, 3:37 PM EDT
Completed Phase 2 Interventional

Chemotherapy in Treating Patients With Advanced Kidney Cancer

NCT00011973
View directory record Official record
Conditions
Kidney Cancer
Interventions
fenretinide
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
4
States / cities
Detroit, Michigan • Rochester, Minnesota • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Oct 19, 2026, 3:37 PM EDT
Completed Phase 1 Interventional

N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma

NCT00295919
View directory record Official record
Conditions
Neuroblastoma
Interventions
fenretinide lipid matrix, ketoconazole, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
0 Years to 30 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 19, 2026, 3:37 PM EDT
Terminated Phase 1Phase 2 Interventional

Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer

NCT01535157
View directory record Official record
Conditions
Ovarian Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasms, Primary Peritoneal Carcinoma
Interventions
Fenretinide/LXS + Ketoconazole
Drug
Lead sponsor
South Plains Oncology Consortium
Network
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Oklahoma City, Oklahoma • Dallas, Texas • Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Oct 19, 2026, 3:37 PM EDT
Terminated Phase 1 Interventional

4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT00102635
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Fenretinide (4-HPR), SCH66336
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 19, 2026, 3:37 PM EDT
Completed Phase 2 Interventional Results available

Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer

NCT00080899
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions
fenretinide, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 19, 2026, 3:37 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

NCT06922539
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Fenretinide
Drug
Lead sponsor
SciTech Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Los Angeles, California • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 19, 2026, 3:37 PM EDT
Completed Phase 1 Interventional

Fenretinide Mucoadhesive Patch: Evaluation of Oral Cancer Prevention Efficacy in Adults With Premalignant Oral Lesions.

NCT07149220
View directory record Official record
Conditions
Oral Leukoplakia, Oral Dysplasia
Interventions
Mucoadhesive fenretinide-releasing system (FMS)
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 100 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 3:37 PM EDT
Suspended Phase 2 Interventional Results available

A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity

NCT00546455
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Fenretinide, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2099
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 19, 2026, 3:37 PM EDT
Completed Phase 2 Interventional

Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer

NCT00003099
View directory record Official record
Conditions
Breast Cancer
Interventions
Fenretinide, Tamoxifen Citrate, Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 19, 2026, 3:37 PM EDT
Completed Not applicable Interventional

Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries

NCT00098800
View directory record Official record
Conditions
brca1 Mutation Carrier, brca2 Mutation Carrier, Ovarian Cancer
Interventions
fenretinide
Drug
Lead sponsor
University of Arizona
Other
Eligibility
30 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 24, 2010 · Synced Oct 19, 2026, 3:37 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults

NCT04417257
View directory record Official record
Conditions
COVID-19 Disease
Interventions
LAU-7b, Placebo oral capsule
Drug
Lead sponsor
Laurent Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
23
States / cities
Chandler, Arizona • Newport Beach, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 19, 2026, 3:37 PM EDT
Completed Phase 1 Interventional

A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer

NCT00001378
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
fenretinide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 3:37 PM EDT
Completed Phase 2 Interventional

Fenretinide in Treating Patients With Recurrent Malignant Glioma

NCT00006080
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
fenretinide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 19, 2026, 3:37 PM EDT
Completed Phase 1 Interventional

Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma

NCT00589381
View directory record Official record
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fenretinide lipid matrix
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 19, 2026, 3:37 PM EDT
Completed Phase 1 Interventional

N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma

NCT00646230
View directory record Official record
Conditions
Neuroblastoma
Interventions
fenretinide, high performance liquid chromatography, pharmacological study
Drug · Other
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
0 Years to 30 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 19, 2026, 3:37 PM EDT
Completed Phase 1 Interventional

Fenretinide in Treating Patients With Solid Tumors

NCT00003250
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fenretinide
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
15 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 11, 2014 · Synced Oct 19, 2026, 3:37 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

NCT00005819
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cisplatin, fenretinide, paclitaxel
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 19, 2026, 3:37 PM EDT